Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 11/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.54 |
| ▸ | DBF4 | Q9UBU7 | 11/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.54 |
| ▸ | CDK2 | P24941 | 10/20 | 0.54 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24699339 | 0.76 | CDC7 (0.51) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL614653 | 0.75 | CDC7 (0.57) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL613530 | 0.70 | CDC7 (1.00) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL613712 | 0.68 | CDC7 (0.64) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL614055 | 0.68 | CDC7 (0.57) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL612624 | 0.67 | CDC7 (0.69) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL612601 | 0.67 | CDC7 (0.72) | CDC7ROCK1DBF4CCNE1CDK2 | |
| SCHEMBL31411707 | 0.63 | PDK2 (0.37) | ABCC8KCNJ11 | |
| SCHEMBL11514809 | 0.63 | — | — | |
| SCHEMBL17837243 | 0.62 | CDC7 (0.32) | CDC7ROCK1DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230079863-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | CDC7 1/4885ROCK1 2609/4885DBF4 593/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | CDC7 3530/4885ROCK1 620/4885DBF4 4453/4885 |
| US-20230079863-A1 | KHK INHIBITORS | KHK, KHDRBS1, NADK | CDC7 625/4885ROCK1 1150/4885DBF4 2298/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | CDC7 625/4885ROCK1 1150/4885DBF4 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.